Skip to content

BioNTech Co-Founder Says Third Dose Will Be Needed – Prensa Libre

  • by Alba luz Leal
No diría que Binance es la plataforma más fácil para principiantes, pero puede sentir que está seguro dentro de ella. Puede ...
Leer Más
Hoy, veremos una de las criptomonedas más exclusivas: Dogecoin y descubriremos dónde y cómo comprar Dogecoin. En esta guía, aprenderá ...
Leer Más
Este corredor en línea tiene tarifas de negociación bajas y una amplia cartera de instrumentos financieros. Cubriendo más de 135 ...
Leer Más

BioNTech co-founder Ugur Sahin believes people will need to continue to be vaccinated against COVID-19 on a regular basis. Two doses will not be enough. Pfizer-BioNtech’s covid-19 vaccine will require a third booster, Ugur Sahin, co-founder of German company BioNTech, said this week. In a video conference, Sahin said this extra dose would be needed to maintain the high levels of protection offered by the vaccine and estimated that it should be given between 9 and 12 months after the first injection. He explained that studies show that the effectiveness of the vaccine declines over time, from 95% to 91% in the first six months. “After eight months, we see that the antibodies generated by the vaccine are reduced. That’s why we need a third dose to bring the vaccine back to almost 100%, ”he said. The possibility that this vaccine requires a third booster had already been suggested in mid-April by Pfizer CEO Albert Bourla. Sahin said he believes it will be necessary for people to continue to be vaccinated against covid-19 on a regular basis every year or every 18 months. Getty Images As with the flu, it is likely that you will need to be vaccinated against the coronavirus every year. Pfizer’s coronavirus vaccine is based on messenger RNA technology. The same as that used by Moderna’s vaccine. The latter company’s CEO, Stéphane Bancel, told US network CNBC in mid-April that they were working on developing a dose booster that they hope to have ready by fall 2021. The idea is that this booster will grant increased immunity against new variants of the coronavirus.